Latest news

Become a Distributor

Andy Boyes appointed as Non-Executive Director to Synapse Electroceutical Limited

Synapse Electroceutical Limited is delighted to announce the appointment of Andy Boyes to the Board. Andy has enjoyed a successful, 32 year career at Smith & Nephew, the FTSE 100 medical technology business engaged in developing, manufacturing, marketing and selling medical devices in the Advanced Wound Management and Advanced Surgical Devices sectors with sales in excess of £4 billion. Andy is passionate
about the wound care sector and helping improve the lives of patients suffering with debilitating complex wounds and since leaving Smith & Nephew has focussed on providing Board level support and strategic direction in the sector.

Read this article

‘The health economic burden that acute and chronic wounds impose on an average clinical commissioning group / health board in the UK’ published in the Journal of Wound Care

It is estimated that the annual prevalence of chronic wounds is growing at the rate of 12%; largely as a result of an average healing rate of 43%. At this growth rate, chronic wounds alone (leg, foot and pressure ulcers) are expected to cost £5.3bn per annum by 2017/2018 and £9.4bn a year in another 5 years time.

Read this article

‘Health economic burden that different wound types impose on the UK’s National Health Service’ published in the International Wound Journal

Of the £5.3 billion the NHS spend every year treating wounds, over £3.0 billion a year is spent on managing chronic wounds (leg ulcers, diabetic foot ulcers and pressure sores) alone. The majority (74%) of this spend was on wounds that did not heal in the year. Healed wounds cost £800 million while unhealed wounds cost £2.2 billion a year; a cost that will be repeated year on year.

Read this article

Other articles

Information for Commissioners

Accel-Heal product shot